ClinicalTrials.gg
TerminatedNCT03646123Updated Aug 28, 2025Results posted

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

A Phase 2 interventional study of brentuximab vedotin and doxorubicin in Hodgkin Lymphoma, sponsored by Seagen Inc.. Terminated at 76 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was prematurely discontinued as the sponsor believes the data collected is enough to show the safety and efficacy of the combinations studied in all cohorts. The decision was not based on any safety and/or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
255
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 52 studies testing nivolumab in Hodgkin Disease — 17 open to participants now, 32 under way, 4 of them phase 3. Nivolumab · Hodgkin Disease.

Enrollment
6th of 52
255 · median 52
Started
2019
with 4 others
Phase 2
33 of 52
12 open now
Registered
25th of 52
by date
Lead sponsor
2 of 52
Seagen Inc.

Among the 52 studies testing nivolumab in Hodgkin Disease, this one is the 6th largest by enrollment, is one of 5 that started in 2019, is one of 33 in phase 2, and was the 25th registered.

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

17 of the 52 studies testing nivolumab in Hodgkin Disease are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing nivolumab in Hodgkin Disease, or all of them as a file.
02

Study summary

This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This trial will find out if these two treatment combinations work to treat cHL. It will also find out what side effects occur. A side effect is anything the drug does besides treating cancer. This study will have three parts (Parts A, B, and C).

The drugs used in Part A are a combination of targeted anticancer drug (brentuximab vedotin) and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs are called "A+AVD." Participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment (12 doses).

Part A will look at whether the A+AVD drug combination reduces the number of participants who experience the side effect of febrile neutropenia. Febrile neutropenia is a very low white blood cell count and a fever, which can be life threatening.

Parts B and C will use drug combination of brentuximab vedotin, plus nivolumab, doxorubicin, and dacarbazine. These four drugs are called "AN+AD." Parts B and C will study how well the drugs work to treat cHL and what side effects they cause.

Read the detailed description

This study will have three parts.

Part A of the study is designed to evaluate the incidence of febrile neutropenia, efficacy, and dose intensity in participants with advanced stage classical Hodgkin lymphoma (cHL) receiving granulocyte colony stimulating factor primary prophylaxis (G-PP) administration during treatment with frontline A+AVD. In Part A, participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment. Participants will be treated using institutional standard of care practices for the majority of treatment decisions.

Part B is designed to evaluate the combination of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) as frontline treatment in participants with advanced cHL. In Part B, participants will be given AN+AD combination for 6 cycles of treatment. This part of the trial will look at whether this combination of drugs is effective and tolerable in participants with Stage II with bulky mediastinal disease and Stage III or IV cHL.

Part C is designed to evaluate AN+AD as frontline treatment in participants with early stage cHL. In Part C, participants will be given AN+AD combination for 4 cycles of treatment. This part of the trial will look at whether this combination of drugs is effective and tolerable in participants with Stage I or II cHL with non-bulky mediastinal disease.

03

Conditions studied

  • Hodgkin Lymphoma

Browse trials for

Keywords

  • Brentuximab vedotin
  • Doxorubicin
  • Vinblastine
  • Dacarbazine
  • Nivolumab
  • Seattle Genetics
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment-naïve, classic Hodgkin lymphoma (cHL) participants

    • Participants enrolling in Part A of the study must have Ann Arbor Stage III or IV disease
    • Participants enrolling in Part B of the study must have Ann Arbor Stage I or II cH: with bulky mediastinal disease, or Stage III or IV
    • Participants enrolling in Part C of the study must have Ann Arbor Stage I or II cHL without bulky disease
  • confirmed cHL according to the current World Health Organization (WHO) Classification
  • Bidimensional as documented by PET/CT or CT imaging
  • Age 12 years or older in the United States. For regions outside of the US, participants must 18 years or older.
  • (ECOG) performance status of 0, 1, or 2

Exclusion criteria

Exclusion Criteria

  • Nodular lymphocyte predominant HL
  • History of another within 3 years of the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk or or death. Participants with nonmelanoma skin cancer, localized prostate cancer, or carcinoma in situ of any type are not excluded if they have undergone complete resection
  • Prior chemotherapy, therapeutic radiation, or any immunotherapy within 4 weeks of the first study drug dose
  • Prior treatment with an , anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Active cerebral/meningeal disease related to the underlying malignancy
  • Any active Grade 3 or higher viral, bacterial, or fungal infection within two weeks of the first dose of study drug (Grade 3 defined by the National Cancer Institute's , NCI CTCAE Version 4.03)
  • Current therapy with other systemic anti-neoplastic or agents
  • Planned consolidative radiotherapy (Parts B and C only)
  • Active interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity (Parts B and C only)
  • Grade 3 or higher pulmonary disease unrelated to underlying malignancy
  • Documented history of idiopathic interstitial pneumonia or diffusing capacity of the lung for carbon monoxide \<50% predicted
  • History of a cerebral vascular event within 6 months of first dose of study drug
  • B or C hepatic impairment
  • Grade 2 or higher peripheral sensory or motor neuropathy
  • Participants with acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment or as prophylaxis against GvHD
  • Previous treatment with brentuximab vedotin
  • Participants who are pregnant or breastfeeding
  • Other serious condition that would impair the participant's ability to receive or tolerate the planned treatment and follow-up
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    Part A: A+AVD

    Brentuximab vedotin (A) plus doxorubicin (+A), vinblastine (V), and dacarbazine (D) administered by intravenous (IV) infusion in participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle.

    Drug: brentuximab vedotin · Drug: doxorubicin · Drug: vinblastine · Drug: dacarbazine · Drug: G-CSF

  • Experimental
    Part B: AN+AD

    Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle.

    Drug: brentuximab vedotin · Drug: doxorubicin · Drug: dacarbazine · Drug: nivolumab

  • Experimental
    Part C: AN+AD

    Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.

    Drug: brentuximab vedotin · Drug: doxorubicin · Drug: dacarbazine · Drug: nivolumab

Interventions

  • 1.2 mg/kg by IV infusion

    Also known as: Adcetris, SGN-35

  • 25 mg/m\^2 by IV infusion

  • 6 mg/m\^2 by IV infusion

  • 375 mg/m\^2 by IV infusion

  • DrugG-CSF

    Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD

    Also known as: filgrastim, pegfilgrastim

  • 240 mg by IV infusion

    Also known as: Opdivo

06

What researchers measure

Primary outcomes

  1. Febrile Neutropenia (FN) Rate (Part A)

    The FN rate is defined as the number of participants who experience treatment-emergent FN.

    Time frame: 7.5 months

  2. Complete Response (CR) Rate at EOT (Parts B and C)

    CR rate at EOT is defined as the percentage of participants with CR at EOT, according to the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) (Cheson 2016), in participants with previously untreated cHL.

    Time frame: 7.8 months

Secondary outcomes

  1. Number of Participants With Adverse Events of Clinical Interest (AECI) (Part A)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with the treatment. Participants with peripheral neuropathy (PN) adverse events were summarized under AECI.

    Time frame: Approximately up to 7.5 months

  2. Primary Refractory Disease Rate (Part A)

    The primary refractory disease rate is defined as the percentage of participants with less than complete response or relapse within 3 months of EOT, according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas

    Time frame: 10.2 months

  3. Complete Response Rate (Part A)

    The complete response rate is defined as the percentage of participants with CR at EOT according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas (Cheson 2014).

    Time frame: 7.2 months

  4. Physician-reported Progression Free Survival (PFS) (Part A)

    The physician-reported PFS rate at 2 years is estimated based on Kaplan-Meier methodology. The determination of antitumor activity will be based on response assessments made according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas (Cheson 2014).

    Time frame: 24 months

  5. Number of Participants With Subsequent Anticancer Therapy Utilization (Part A)

    Number of participants with subsequent anticancer therapy have been reported in this outcome measure.

    Time frame: 33.8 months

  6. Actual Dose Intensity: Brentuximab Vedotin (Part A)

    Time frame: 6.5 months

  7. Actual Dose Intensity: Doxorubicin, Vinblastine, Dacarbazine (Part A)

    Time frame: 6.5 months

  8. Relative Dose Intensity (Part A)

    Time frame: 6.5 months

  9. Rate of Dose Reduction and Delays: Brentuximab Vedotin (Part A)

    Time frame: 6.5 months

  10. Rate of Dose Reduction and Delays: Doxorubicin (Part A)

    Time frame: 6.5 months

  11. Rate of Dose Reduction and Delays: Vinblastine (Part A)

    Time frame: 6.5 months

  12. Rate of Dose Reduction and Delays: Dacarbazine (Part A)

    Time frame: 6.5 months

  13. Incidence of Adverse Events (Parts B and C)

    Time frame: 8.9 months

  14. Incidence of Laboratory Abnormalities (Parts B and C)

    Laboratory values were graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.03). As per NCI CTCAE version 4.03 grading, Grade 1 indicated mild or asymptomatic laboratory abnormalities, Grade 2 indicated moderate laboratory abnormalities, and Grade 3 indicated severe and 4 indicated life-threatening laboratory abnormalities.

    Time frame: 8.9 months

  15. Overall Response Rate (ORR) at EOT (Parts B and C)

    ORR is defined as the percentage of participants with CR or partial response (PR) at EOT according to the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) in participants with previously untreated cHL.

    Time frame: Up to 7.8 months

  16. Duration of Response (DOR) at End of Study (Parts B and C)

    DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) or death, whichever came first. Duration of response was only calculated for the subgroup of participants achieving a CR or PR. Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.

    Time frame: Up to 51.1 months

  17. Duration of Complete Response (DOCR) (Parts B and C)

    DOCR was defined as the time from start of the first documentation of CR to the first documentation of tumor progression (per the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) or death, whichever came first. DOCR was calculated for the subgroup of participants achieving CR. Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.

    Time frame: Up to 51.1 months

  18. Event Free Survival (EFS) Rate (Parts B and C)

    EFS was defined as the time from the start of study treatment to the first documentation of objective tumor progression, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or progressive disease, whichever occurred first. The determination of antitumor activity will be based on objective response assessments made according to Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016). Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. EFS rate was percentage of participants with EFS.

    Time frame: Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42

  19. PFS Rate (Parts B and C)

    PFS was defined as the time from start of study treatment to first documentation of objective tumor progression or death. The determination of antitumor activity will be based on objective response assessments made according to Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016). Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.

    Time frame: At months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42 from the start of study treatment

  20. Overall Survival (OS) Rate (Parts B and C)

    OS was defined as the time from start of study treatment to date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. Kaplan-Meier method was used.

    Time frame: At months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42 from the start of study treatment

07

Results

Posted Dec 21, 2023

Participant flow

Participant flow — Overall Study
MilestonePart APart BPart C
Started4158156
Treated4057154
Completed3101
Not completed1058155
Withdrew: Withdrawal by subject223
Withdrew: Study termination by sponsor045139
Withdrew: Lost to follow-up41010
Withdrew: Death211
Withdrew: Other202

Outcome measures

PrimaryFebrile Neutropenia (FN) Rate (Part A)

The FN rate is defined as the number of participants who experience treatment-emergent FN.

Time frame:
7.5 months
Reported as:
Count of participants · Participants
Febrile Neutropenia (FN) Rate (Part A)
ParticipantsPart A
Any treatment-emergent FN5
Treatment-related treatment-emergent FN5
Grade 3 or higher treatment-emergent FN5
Grade 3 or higher treatment-related treatment-emergent FN5
PrimaryComplete Response (CR) Rate at EOT (Parts B and C)

CR rate at EOT is defined as the percentage of participants with CR at EOT, according to the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) (Cheson 2016), in participants with previously untreated cHL.

Time frame:
7.8 months
Reported as:
Number · Percentage of participants
Complete Response (CR) Rate at EOT (Parts B and C)
Percentage of participantsPart BPart C
Complete Response (CR) Rate at EOT (Parts B and C)88 (76.3 to 94.9)92 (86.0 to 95.4)
SecondaryNumber of Participants With Adverse Events of Clinical Interest (AECI) (Part A)

An adverse event (AE) was any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which did not necessarily have a causal relationship with the treatment. Participants with peripheral neuropathy (PN) adverse events were summarized under AECI.

Time frame:
Approximately up to 7.5 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Clinical Interest (AECI) (Part A)
ParticipantsPart A
Number of Participants With Adverse Events of Clinical Interest (AECI) (Part A)32
SecondaryPrimary Refractory Disease Rate (Part A)

The primary refractory disease rate is defined as the percentage of participants with less than complete response or relapse within 3 months of EOT, according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas

Time frame:
10.2 months
Reported as:
Number · percentage of participants
Primary Refractory Disease Rate (Part A)
percentage of participantsPart A
Primary Refractory Disease Rate (Part A)10 (2.8 to 23.7)
SecondaryComplete Response Rate (Part A)

The complete response rate is defined as the percentage of participants with CR at EOT according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas (Cheson 2014).

Time frame:
7.2 months
Reported as:
Number · percentage of participants
Complete Response Rate (Part A)
percentage of participantsPart A
Complete Response Rate (Part A)80 (64.4 to 90.9)
SecondaryPhysician-reported Progression Free Survival (PFS) (Part A)

The physician-reported PFS rate at 2 years is estimated based on Kaplan-Meier methodology. The determination of antitumor activity will be based on response assessments made according to the Lugano Classification Revised Staging System for nodal non-Hodgkin and Hodgkin lymphomas (Cheson 2014).

Time frame:
24 months
Reported as:
Number · percentage of participants
Physician-reported Progression Free Survival (PFS) (Part A)
percentage of participantsPart A
Physician-reported Progression Free Survival (PFS) (Part A)89.23 (73.76 to 95.82)
SecondaryNumber of Participants With Subsequent Anticancer Therapy Utilization (Part A)

Number of participants with subsequent anticancer therapy have been reported in this outcome measure.

Time frame:
33.8 months
Reported as:
Count of participants · Participants
Number of Participants With Subsequent Anticancer Therapy Utilization (Part A)
ParticipantsPart A
Participants with any subsequent therapy6
Consolidative radiotherapy: Radiotherapy3
Consolidative radiotherapy: Proton radiation1
Immunotherapy: Nivolumab1
Maintenance: Nivolumab1
Maintenance radiotherapy: Radiation therapy1
Systemic therapy for progressive disease: Bendamustine monotherapy1
Systemic therapy for relapsed disease: Nivolumab1
SecondaryActual Dose Intensity: Brentuximab Vedotin (Part A)
Time frame:
6.5 months
Reported as:
Mean · mg/kg/week
Actual Dose Intensity: Brentuximab Vedotin (Part A)
mg/kg/weekPart A
Actual Dose Intensity: Brentuximab Vedotin (Part A)0.5 ± 0.1
SecondaryActual Dose Intensity: Doxorubicin, Vinblastine, Dacarbazine (Part A)
Time frame:
6.5 months
Reported as:
Mean · mg/m2/week
Actual Dose Intensity: Doxorubicin, Vinblastine, Dacarbazine (Part A)
mg/m2/weekPart A
Doxorubicin11.8 ± 1.0
Vinblastine2.7 ± 0.4
Dacarbazine176.3 ± 15.2
SecondaryRelative Dose Intensity (Part A)
Time frame:
6.5 months
Reported as:
Mean · percentage of intended dose
Relative Dose Intensity (Part A)
percentage of intended dosePart A
Brentuximab vedotin91.0 ± 10.8
Doxorubicin94.2 ± 8.2
Vinblastine89.0 ± 13.6
Dacarbazine94.0 ± 8.1
SecondaryRate of Dose Reduction and Delays: Brentuximab Vedotin (Part A)
Time frame:
6.5 months
Reported as:
Count of participants · Participants
Rate of Dose Reduction and Delays: Brentuximab Vedotin (Part A)
ParticipantsPart A
Participants with any dose modification29
Participants with any dose delay22
Participants with any dose delay due to AE15
Participants with any dose delay due to other reason14
Participants with any dose reduction due to AE14
SecondaryRate of Dose Reduction and Delays: Doxorubicin (Part A)
Time frame:
6.5 months
Reported as:
Count of participants · Participants
Rate of Dose Reduction and Delays: Doxorubicin (Part A)
ParticipantsPart A
Participants with any dose modification25
Participants with any dose delay23
Participants with any dose delay due to AE15
Participants with any dose delay due to other reason15
Participants with any dose reduction due to AE7
SecondaryRate of Dose Reduction and Delays: Vinblastine (Part A)
Time frame:
6.5 months
Reported as:
Count of participants · Participants
Rate of Dose Reduction and Delays: Vinblastine (Part A)
ParticipantsPart A
Participants with any dose modification27
Participants with any dose delay22
Participants with any dose delay due to AE15
Participants with any dose delay due to other reason14
Participants with any dose reduction due to AE12
SecondaryRate of Dose Reduction and Delays: Dacarbazine (Part A)
Time frame:
6.5 months
Reported as:
Count of participants · Participants
Rate of Dose Reduction and Delays: Dacarbazine (Part A)
ParticipantsPart A
Participants with any dose modification25
Participants with any dose delay22
Participants with any dose delay due to AE15
Participants with any dose delay due to other reason14
Participants with any dose reduction due to AE6
SecondaryIncidence of Adverse Events (Parts B and C)
Time frame:
8.9 months
Reported as:
Count of participants · Participants
Incidence of Adverse Events (Parts B and C)
ParticipantsPart BPart C
Any treatment-emergent adverse event (TEAE)57153
Treatment-related TEAE56149
Grade 3 or higher TEAE2967
Grade 3 or higher treatment-related TEAE1952
Any treatment-emergent serious adverse event (SAE)1529
Treatment-related treatment-emergent SAE819
Participants who discontinued treatment due to TEAE44
Participants who discontinued treatment due to treatment-related TEAE44
TEAE leading to death00
SecondaryIncidence of Laboratory Abnormalities (Parts B and C)

Laboratory values were graded according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.03). As per NCI CTCAE version 4.03 grading, Grade 1 indicated mild or asymptomatic laboratory abnormalities, Grade 2 indicated moderate laboratory abnormalities, and Grade 3 indicated severe and 4 indicated life-threatening laboratory abnormalities.

Time frame:
8.9 months
Reported as:
Count of participants · Participants
Incidence of Laboratory Abnormalities (Parts B and C)
ParticipantsPart BPart C
Hemoglobin high, Grade 104
Hemoglobin high, Grade 200
Hemoglobin high, Grade 300
Hemoglobin high, Grade 400
Hemoglobin low, Grade 13796
Hemoglobin low, Grade 2106
Hemoglobin low, Grade 311
Hemoglobin low, Grade 400
Leukocytes high, Grade 100
Leukocytes high, Grade 200
Leukocytes high, Grade 300
Leukocytes high, Grade 400
Leukocytes low, Grade 11941
Leukocytes low, Grade 21224
Leukocytes low, Grade 302
Leukocytes low, Grade 400
Lymphocytes high, Grade 100
Lymphocytes high, Grade 213
Lymphocytes high, Grade 300
Lymphocytes high, Grade 400
Lymphocytes low, Grade 11131
Lymphocytes low, Grade 21722
Lymphocytes low, Grade 379
Lymphocytes low, Grade 410
Neutrophils low, Grade 1412
Neutrophils low, Grade 21438
Neutrophils low, Grade 3411
Neutrophils low, Grade 423
Platelets low, Grade 1622
Platelets low, Grade 211
Platelets low, Grade 300
Platelets low, Grade 400
Alanine aminotransferase high, Grade 12671
Alanine aminotransferase high, Grade 2316
Alanine aminotransferase high, Grade 3410
Alanine aminotransferase high, Grade 400
Albumin low, Grade 11122
Albumin low, Grade 236
Albumin low, Grade 300
Albumin low, Grade 400
Alkaline phosphatase high, Grade 13051
Alkaline phosphatase high, Grade 221
Alkaline phosphatase high, Grade 300
Alkaline phosphatase high, Grade 400
Amylase high, Grade 1315
Amylase high, Grade 226
Amylase high, Grade 306
Amylase high, Grade 400
Aspartate aminotransferase high, Grade 12775
Aspartate aminotransferase high, Grade 217
Aspartate aminotransferase high, Grade 321
Aspartate aminotransferase high, Grade 400
Calcium corrected for albumin high, Grade 11218
Calcium corrected for albumin high, Grade 200
Calcium corrected for albumin high, Grade 300
Calcium corrected for albumin high, Grade 400
Calcium corrected for albumin low, Grade 175
Calcium corrected for albumin low, Grade 201
Calcium corrected for albumin low, Grade 300
Calcium corrected for albumin low, Grade 400
Ionized calcium high, Grade 100
Ionized calcium high, Grade 200
Ionized calcium high, Grade 300
Ionized calcium high, Grade 400
Ionized calcium low, Grade 100
Ionized calcium low, Grade 200
Ionized calcium low, Grade 300
Ionized calcium low, Grade 400
Creatinine high, Grade 147127
Creatinine high, Grade 2511
Creatinine high, Grade 310
Creatinine high, Grade 400
Estimated glomerular filtration rate low, Grade 118
Estimated glomerular filtration rate low, Grade 2410
Estimated glomerular filtration rate low, Grade 300
Estimated glomerular filtration rate low, Grade 400
Glucose high, Grade 14569
Glucose high, Grade 259
Glucose high, Grade 3113
Glucose high, Grade 410
Glucose low, Grade 11218
Glucose low, Grade 210
Glucose low, Grade 300
Glucose low, Grade 400
Lipase high, Grade 1913
Lipase high, Grade 216
Lipase high, Grade 356
Lipase high, Grade 403
Phosphate low, Grade 113
Phosphate low, Grade 279
Phosphate low, Grade 324
Phosphate low, Grade 400
Potassium high, Grade 137
Potassium high, Grade 201
Potassium high, Grade 300
Potassium high, Grade 400
Potassium low, Grade 1919
Potassium low, Grade 200
Potassium low, Grade 320
Potassium low, Grade 410
Sodium high, Grade 123
Sodium high, Grade 200
Sodium high, Grade 301
Sodium high, Grade 400
Sodium low, Grade 11125
Sodium low, Grade 200
Sodium low, Grade 322
Sodium low, Grade 400
Total bilirubin high, Grade 118
Total bilirubin high, Grade 220
Total bilirubin high, Grade 300
Total bilirubin high, Grade 400
Urate high, Grade 100
Urate high, Grade 200
Urate high, Grade 31028
Urate high, Grade 401
SecondaryOverall Response Rate (ORR) at EOT (Parts B and C)

ORR is defined as the percentage of participants with CR or partial response (PR) at EOT according to the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) in participants with previously untreated cHL.

Time frame:
Up to 7.8 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) at EOT (Parts B and C)
Percentage of participantsPart BPart C
Overall Response Rate (ORR) at EOT (Parts B and C)93 (83.0 to 98.1)96 (91.7 to 98.6)
SecondaryDuration of Response (DOR) at End of Study (Parts B and C)

DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) or death, whichever came first. Duration of response was only calculated for the subgroup of participants achieving a CR or PR. Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.

Time frame:
Up to 51.1 months
Reported as:
Median · Months
Duration of Response (DOR) at End of Study (Parts B and C)
MonthsPart BPart C
Duration of Response (DOR) at End of Study (Parts B and C)NA (NA to NA)NA (NA to NA)
SecondaryDuration of Complete Response (DOCR) (Parts B and C)

DOCR was defined as the time from start of the first documentation of CR to the first documentation of tumor progression (per the Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016) or death, whichever came first. DOCR was calculated for the subgroup of participants achieving CR. Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.

Time frame:
Up to 51.1 months
Reported as:
Median · Months
Duration of Complete Response (DOCR) (Parts B and C)
MonthsPart BPart C
Duration of Complete Response (DOCR) (Parts B and C)NA (NA to NA)NA (NA to NA)
SecondaryEvent Free Survival (EFS) Rate (Parts B and C)

EFS was defined as the time from the start of study treatment to the first documentation of objective tumor progression, death due to any cause, or receipt of subsequent anticancer therapy to treat residual or progressive disease, whichever occurred first. The determination of antitumor activity will be based on objective response assessments made according to Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016). Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. EFS rate was percentage of participants with EFS.

Time frame:
Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42
Reported as:
Number · Percentage of participants
Event Free Survival (EFS) Rate (Parts B and C)
Percentage of participantsPart BPart C
Month 398.25 (88.19 to 99.75)100 (100 to 100)
Month 698.25 (88.19 to 99.75)98.66 (94.74 to 99.66)
Month 994.67 (84.39 to 98.25)98.66 (94.74 to 99.66)
Month 1292.89 (82.15 to 97.27)98.66 (94.74 to 99.66)
Month 1591.03 (79.77 to 96.17)97.95 (93.79 to 99.34)
Month 1891.03 (79.77 to 96.17)96.46 (91.70 to 98.51)
Month 2186.89 (74.38 to 93.55)96.46 (91.70 to 98.51)
Month 2486.89 (74.38 to 93.55)95.62 (90.49 to 98.02)
Month 2786.89 (74.38 to 93.55)94.72 (89.19 to 97.46)
Month 3086.89 (74.38 to 93.55)94.72 (89.19 to 97.46)
Month 3384.54 (71.29 to 92.01)94.72 (89.19 to 97.46)
Month 3684.54 (71.29 to 92.01)94.72 (89.19 to 97.46)
Month 3984.54 (71.29 to 92.01)94.72 (89.19 to 97.46)
Month 4284.54 (71.29 to 92.01)—
SecondaryPFS Rate (Parts B and C)

PFS was defined as the time from start of study treatment to first documentation of objective tumor progression or death. The determination of antitumor activity will be based on objective response assessments made according to Lugano Classification Revised Staging System for malignant lymphoma (Cheson 2014) with the incorporation of LYRIC (Cheson 2016). Participants without progression or death were censored on the date of the last radiological assessment of measured lesions. Kaplan-Meier method was used.

Time frame:
At months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42 from the start of study treatment
Reported as:
Number · Percentage of participants
PFS Rate (Parts B and C)
Percentage of participantsPart BPart C
Month 3100 (100 to 100)100 (100 to 100)
Month 6100 (100 to 100)100 (100 to 100)
Month 996.36 (86.23 to 99.08)100 (100 to 100)
Month 1294.55 (84.04 to 98.21)100 (100 to 100)
Month 1592.65 (81.59 to 97.18)99.29 (95.04 to 99.90)
Month 1892.65 (81.59 to 97.18)97.77 (93.26 to 99.28)
Month 2188.44 (76.00 to 94.65)97.77 (93.26 to 99.28)
Month 2488.44 (76.00 to 94.65)96.92 (91.99 to 98.84)
Month 2788.44 (76.00 to 94.65)96.01 (90.64 to 98.33)
Month 3088.44 (76.00 to 94.65)96.01 (90.64 to 98.33)
Month 3386.05 (72.80 to 93.14)96.01 (90.64 to 98.33)
Month 3686.05 (72.80 to 93.14)96.01 (90.64 to 98.33)
Month 3986.05 (72.80 to 93.14)96.01 (90.64 to 98.33)
Month 4286.05 (72.80 to 93.14)—
SecondaryOverall Survival (OS) Rate (Parts B and C)

OS was defined as the time from start of study treatment to date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. Kaplan-Meier method was used.

Time frame:
At months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39 and 42 from the start of study treatment
Reported as:
Number · Percentage of participants
Overall Survival (OS) Rate (Parts B and C)
Percentage of participantsPart BPart C
Month 3100 (100 to 100)100 (100 to 100)
Month 6100 (100 to 100)100 (100 to 100)
Month 9100 (100 to 100)100 (100 to 100)
Month 1298.25 (88.19 to 99.75)100 (100 to 100)
Month 1598.25 (88.19 to 99.75)100 (100 to 100)
Month 1898.25 (88.19 to 99.75)100 (100 to 100)
Month 2198.25 (88.19 to 99.75)100 (100 to 100)
Month 2498.25 (88.19 to 99.75)100 (100 to 100)
Month 2798.25 (88.19 to 99.75)100 (100 to 100)
Month 3098.25 (88.19 to 99.75)100 (100 to 100)
Month 3398.25 (88.19 to 99.75)98.73 (91.35 to 99.82)
Month 3698.25 (88.19 to 99.75)98.73 (91.35 to 99.82)
Month 3998.25 (88.19 to 99.75)98.73 (91.35 to 99.82)
Month 4298.25 (88.19 to 99.75)98.73 (91.35 to 99.82)

Adverse events

Collected over All-Cause Mortality: Up to 54.5 Months, Serious Adverse Events, and Non-Serious Adverse Events were followed for up to 8.9 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A2/40 (5%)19/40 (47.5%)40/40 (100%)
Part B1/57 (1.8%)15/57 (26.3%)57/57 (100%)
Part C1/154 (0.6%)29/154 (18.8%)153/154 (99.4%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventPart APart BPart C
Febrile neutropeniaBlood and lymphatic system disorders5/400/570/154
PneumoniaInfections and infestations4/400/572/154
PyrexiaGeneral disorders3/403/576/154
PneumonitisRespiratory, thoracic and mediastinal disorders1/403/572/154
Abdominal painGastrointestinal disorders2/400/570/154
PainGeneral disorders2/400/570/154
HypotensionVascular disorders2/400/570/154
COVID-19 pneumoniaInfections and infestations0/402/570/154
SepsisInfections and infestations0/402/571/154
AnaemiaBlood and lymphatic system disorders1/400/570/154
Most frequent other events
Showing 10 of 416
Most frequent other events
EventPart APart BPart C
NauseaGastrointestinal disorders28/4040/57105/154
Peripheral sensory neuropathyNervous system disorders25/4026/5772/154
FatigueGeneral disorders15/4029/5774/154
DiarrhoeaGastrointestinal disorders13/4026/5738/154
ConstipationGastrointestinal disorders18/4022/5769/154
AlopeciaSkin and subcutaneous tissue disorders12/4021/5734/154
HeadacheNervous system disorders13/4015/5736/154
Bone painMusculoskeletal and connective tissue disorders12/4010/5710/154
VomitingGastrointestinal disorders9/4016/5725/154
Decreased appetiteMetabolism and nutrition disorders11/409/5722/154

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part APart BPart CTotal
Median28 (18 to 71)35 (19 to 78)31 (18 to 77)31 (18 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Part APart BPart CTotal
Female162786129
Male253170126
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part APart BPart CTotal
Hispanic or Latino4102236
Not Hispanic or Latino3446127207
Unknown or Not Reported32712
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part APart BPart CTotal
American Indian or Alaska Native0011
Asian1168
Native Hawaiian or Other Pacific Islander0000
Black or African American6219
White3150131212
More than one race0101
Unknown or Not Reported341724
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Part APart BPart CTotal
Grade 02734124185
Grade 113232864
Grade 20022
Missing1124
08

Study locations

76 sites
  • Los Angeles Cancer Network / Compassionate Care Research Group
    Fountain Valley, California 92708, United States
  • Rocky Mountain Cancer Centers - Aurora
    Aurora, Colorado 80012, United States
  • University of Colorado Health Memorial Hospital
    Colorado Springs, Colorado 80909, United States
  • Cancer Centers of Colorado - Denver
    Denver, Colorado 80218, United States
  • Poudre Valley Health System (PVHS)
    Fort Collins, Colorado 80528, United States
  • SCL Health - St. Mary's Hospital & Medical Center
    Grand Junction, Colorado 81501, United States
  • Miami Cancer Institute at Baptist Health, Inc.
    Miami, Florida 33176, United States
  • Florida Cancer Specialists - North Region
    St. Petersburg, Florida 33705, United States
  • Cardinal Bernardin Cancer Center / Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Illinois Cancer Specialists
    Niles, Illinois 60714, United States
  • Illinois Cancer Care
    Peoria, Illinois 61615, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute / Wayne State University
    Detroit, Michigan 48201, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Minnesota Oncology Hematology P.A.
    Edina, Minnesota 55435, United States
  • Washington University in St Louis
    St Louis, Missouri 63110, United States
  • New Jersey Hematology Oncology Associates, LLC
    Brick, New Jersey 08724, United States
  • Regional Cancer Care Associates - Freehold
    Freehold, New Jersey 07728, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Regional Cancer Care Associates - Howell
    Howell Township, New Jersey 07731, United States
  • Morristown Medical Center/ Carol G. Simon Cancer Center
    Morristown, New Jersey 07960, United States
  • Regional Cancer Care Associates - Mount Holly
    Mount Holly, New Jersey 08060, United States
  • Regional Cancer Care Associates - Central Jersey
    Somerville, New Jersey 08876, United States
  • Regional Cancer Care Associates - Sparta
    Sparta, New Jersey 07871, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12208, United States
  • CareMount Medical Group
    Mount Kisco, New York 10549-3412, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Clinical Research Alliance - Abraham Mittelman, MD, LLC
    Purchase, New York 10577, United States
  • Clinical Research Alliance - Morton Coleman, MD
    Westbury, New York 11590, United States
  • Wake Forest Baptist Medical Center / Wake Forest University
    Winston-Salem, North Carolina 27157, United States
  • Oncology Hematology Care
    Cincinnati, Ohio 45242, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic, The
    Cleveland, Ohio 44195, United States
  • Toledo Clinic Cancer Center
    Toledo, Ohio 43623, United States
  • Willamette Valley Cancer Institute and Research Center
    Eugene, Oregon 97401, United States
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
  • Medical University of South Carolina/Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • University of Tennessee
    Knoxville, Tennessee 37920, United States
  • Tennessee Oncology-Nashville/Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Texas Oncology - Austin Midtown
    Austin, Texas 78705, United States
  • Texas Oncology - Medical City Dallas
    Dallas, Texas 75230, United States
  • Texas Oncology - Flower Mound
    Flower Mound, Texas 75028, United States
  • Brooke Army Medical Center
    Fort Sam Houston, Texas 78234, United States
  • Texas Oncology - Fort Worth 12th Avenue
    Fort Worth, Texas 76104, United States
  • MD Anderson Cancer Center / University of Texas
    Houston, Texas 77030-4095, United States
  • Texas Oncology - San Antonio Medical Center
    San Antonio, Texas 78240, United States
  • Texas Oncology - Northeast Texas
    Tyler, Texas 75702, United States
  • Huntsman Cancer Institute/University of Utah
    Salt Lake City, Utah 84112, United States
  • Virginia Cancer Specialists, PC
    Fairfax, Virginia 22031, United States
  • Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
    Salem, Virginia 24153, United States
  • Kadlec Clinic Hematology and Oncology
    Kennewick, Washington 99336, United States
  • Vista Oncology Inc PS
    Olympia, Washington 98506, United States
  • Seattle Cancer Care Alliance / University of Washington
    Seattle, Washington 98109-1023, United States
  • Royal Adelaide Hospital
    Adelaide, Other 5000, Australia
  • Ballarat Regional Integrated Cancer Care
    Ballarat, Other 3350, Australia
  • Monash Medical Centre
    Clayton, Other 3168, Australia
  • Epworth Healthcare
    Victoria, Other 3002, Australia
  • Fakultni nemocnice Hradec Kralove-oddeleni klinicke hematologie
    Hradec Králové, Other 500 05, Czechia
  • Fakultni Nemocnice Kralovske Vinohrady
    Prague, Other 100 34, Czechia
  • Azienda Ospedaliera Spedali Civili di Brescia
    Brescia, Other 25123, Italy
  • IRCSS Policlinico San Matteo
    Pavia, Other 27100, Italy
  • Azienda Ospedaliera Universitaria Senese
    Siena, Other 53100, Italy
  • Azienda Ospedaliera Citta della Salute e della Scienza di Torino
    Torino, Other 10126, Italy
  • Pratia MCM Krakow
    Krakow, Other 30-727, Poland
  • Hospital del Mar
    Barcelona, Other 08003, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Other 08035, Spain
  • Institut Catala d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)
    Barcelona, Other 08908, Spain
  • Hospital Universitario de Girona Doctor Josep Trueta
    Girona, Other 17007, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, Other 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Other 28041, Spain
  • Hospital Puerta de Hierro Majadahonda
    Majadahonda, Other 28222, Spain
  • Hospital Universitario Central de Asturias
    Oviedo, Other 33011, Spain
  • Hospital Clinico Universitario de Salamanca
    Salamanca, Other 37007, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, Other 46026, Spain
09

References and documents

Publications

  • Abramson JS, Straus DJ, Bartlett NL, Burke JM, Lynch RC, Domingo Domenech E, Hess B, Schuster SR, Linhares Y, Gandhi M, Shah HR, Jurczak W, Re A, Hahn U, Prince HM, Guo W, Davis G, Ho L, Fanale M, Yasenchak CA, Lee HJ. Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary. Future Oncol. 2026 Jul 6:1-14. doi: 10.1080/14796694.2026.2693614. Online ahead of print. PubMed 42405616 ↗
  • Abramson JS, Straus DJ, Bartlett NL, Burke JM, Lynch RC, Domingo Domenech E, Hess B, Schuster SR, Linhares Y, Gandhi M, Shah HR, Jurczak W, Re A, Hahn U, Prince HM, Guo W, Davis G, Ho L, Fanale M, Yasenchak CA, Lee HJ. Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma. Blood. 2026 Apr 9;147(15):1713-1722. doi: 10.1182/blood.2025030190. PubMed 41460964 ↗
  • Lee HJ, Ramchandren R, Friedman J, Melear J, Flinn IW, Burke JM, Linhares Y, Gonzales P, Peterson M, Raval M, Chintapatla R, Feldman TA, Yimer H, Islas-Ohlmayer M, Patel A, Metheny L, Dean A, Rana V, Gandhi MD, Renshaw J, Ho L, Fanale MA, Guo W, Yasenchak CA. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025 Jan 16;145(3):290-299. doi: 10.1182/blood.2024024681. PubMed 39622165 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Nov 2022, 45 months.

Results were first posted in Dec 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2018
First posted
Aug 24, 2018
StartActual
Jan 28, 2019
Primary completionActual
Nov 7, 2022
CompletionActual
Aug 23, 2024
Results first posted
Dec 21, 2023
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03646123
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Aug 24, 2018
Start date
Jan 28, 2019
Primary completion
Nov 7, 2022
Completion
Aug 23, 2024
Results posted
Dec 21, 2023
Last update
Aug 28, 2025

Study contacts

Medical Monitor
study director · Seagen Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion